Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologic (or cytologic) proof of colorectal carcinoma (CRC).~2. Age: between 18 and 80.~3. Sex: both sexes.~4. Previous treatment for metastatic disease is limited to FOLFIRI+ bevacizumab.~5. Prior adjuvant chemotherapy, with a fluoropyrimidine and/or Oxaliplatin, is allowed.~6. Prior radiotherapy, either as adjuvant treatment or palliation of metastatic sites is allowed, provided that there are other non-irradiated foci of disease for evaluation.~7. Persistent remission, either complete, partial or minimal response (CR, PR or MR) or stable disease (SD), one year+/-one month from initiation of first line treatment for mCRC.~8. Asymptomatic patients at break from chemotherapy.~9. Intact organ function, including complete blood counts (CBC) showing normal values or any toxicity limited to grade 1 and blood chemistry (SMA) showing liver and renal functions \< 1.5 upper normal limit (UNL).~10. Capability to understand and to sign the informed consent.~Exclusion Criteria:~1. Concurrent any other cancer (except BCC or squamous cell carcinoma of skin).~2. Inability to adhere to monthly visits to the oncology unit for evaluation.~3. Presence of brain metastases.~4. Any current or recent (within the last month) continuous treatment by steroids or by NSAIDs, or with therapeutic doses of anticoagulants for any reason.~5. Previous radiotherapy to the only site of measurable disease.~6. Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac including arrhythmias, hepatic or renal disease), and/or existence of active peptic ulcer (clinically and/or by gastroscopy).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- LDM anti-angiogenic chemotherapy (Type: EXPERIMENTAL): LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
- observation (Type: NO_INTERVENTION): observation only

Based on this trial design, predict the completion outcome and termination type (if applicable).